Microfluidic Lung

微流控肺

• 批准号: 7404347
• 负责人: Anna M Galea
• 金额: $ 20万
• 依托单位: INFOSCITEX CORPORATION
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-09-15 至 2009-12-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7404347
• 关键词: Acute; Address; Air; Animal Experiments; Animals; Anticoagulation; Area; Blood; Blood Clot; Blood coagulation; Blood flow; Blood gas; Carbon Dioxide; Cells; Chronic; Chronic Care; Clinical; Clinical Medicine; Commit; Condition; Containment; Development; Device Designs; Devices; Drops; Environment; Equilibrium; Equipment Malfunction; Evaluation; Facility Construction Funding Category; Family suidae; Fiber; Gases; Goals; Government; Grant; Heart-Lung Machine; Hour; Implant; In Vitro; Lead; Life; Liquid substance; Lung; Membrane; Microfluidic Microchips; Microfluidics; Operative Surgical Procedures; Oxygen; Oxygenators; Peripheral; Persons; Phase; Preparation; Public Health; Purpose; Rate; Scientist; Small Business Funding Mechanisms; Small Business Innovation Research Grant; Solutions; Staging; Sterility; Stream; Surface; System; Technology; Testing; Thrombosis; United States National Institutes of Health; Whole Blood; Work; artificial lung; blood oxygenator; concept; design; fluid flow; in vivo; novel; pressure; programs; prototype; research study; respiratory; respiratory assist; scale up; size; success; technology development

DESCRIPTION (provided by applicant): We propose to develop a novel microfluidic approach that will enable the realization of a truly long-term implantable artificial lung. There have been considerable advances in membrane oxygenation, including our own previous work in creating a hollow fiber membrane array that is more efficient than natural lungs at gas exchange with room air. Despite these advances, the underlying fiber technology presents a large surface area to blood, causing fouling of the membrane and activation of the blood, which increases the chance of blood clots and often necessitates the need for anticoagulation therapy. Our novel solution incorporates the previous work to perform gas exchange with air but utilizes microfluidic technology to perform gas exchange with blood in a membrane-free manner. In this proposal we present our previous work towards this development including our initial analysis of the device design and efficiency. By the end of Phase I we will have demonstrated the feasibility of our approach and prepared detailed drawings of an integrated artificial lung design that we will further develop in Phase II and test in animal studies. Infoscitex is fully committed to realizing our end goal of a fully implantable artificial lung and stands to make a considerable impact in the field of respiratory assist devices with this technology and acute support devices developed in parallel. PUBLIC HEALTH RELEVANCE: The concept of using an artificial lung in clinical medicine to take over the gas exchange function of the native lung dates to the development of the heart-lung machine in 1954. Most blood gas exchange devices utilize membranes to perform the gas exchange, which damages the blood and can cause dangerous blood clots. More recently, some scientists have explored adding a highly oxygenated liquid directly into the blood, removing the liquid downstream from the insertion point. While less damaging to the blood, these systems have limited means of removing carbon dioxide from blood and cannot be used in a chronic condition. Our system utilizes the best of the concepts from these two approaches and builds on our previous work to develop a membraneless interface to the blood for exchanging both oxygen and carbon dioxide between blood and room air. Our final end goal is to develop a completely implantable artificial lung for chronic care, although our technology can be used for other parallel devices along the way to this end goal.

描述（由申请人提供）：我们提出开发一种新的微流体方法，该方法将能够实现真正的长期植入式人工肺。在膜氧合方面已经有了相当大的进展，包括我们自己以前在创造中空纤维膜阵列方面的工作，该中空纤维膜阵列在与室内空气进行气体交换时比天然肺更有效。尽管有这些进步，但潜在的纤维技术对血液呈现出大的表面积，导致膜污染和血液活化，这增加了血液凝块的机会，并且通常需要抗凝治疗。我们的新解决方案结合了以前的工作，与空气进行气体交换，但利用微流体技术以无膜方式与血液进行气体交换。在这个建议中，我们提出了我们以前的工作，包括我们的设备设计和效率的初步分析。到第一阶段结束时，我们将证明我们的方法的可行性，并准备了一个集成的人工肺设计的详细图纸，我们将在第二阶段进一步开发和动物研究测试。Infoscitex完全致力于实现我们完全植入式人工肺的最终目标，并将通过这项技术和并行开发的急性支持设备在呼吸辅助设备领域产生相当大的影响。公共卫生关系：在临床医学中使用人工肺来接管天然肺的气体交换功能的概念可以追溯到1954年心肺机的发展。大多数血液气体交换装置利用膜来进行气体交换，这会损害血液并可能导致危险的血液凝块。最近，一些科学家已经探索将高度含氧的液体直接加入血液中，从插入点的下游移除液体。虽然对血液的损害较小，但这些系统从血液中去除二氧化碳的方法有限，不能用于慢性疾病。我们的系统利用了这两种方法中最好的概念，并建立在我们以前的工作基础上，开发了一种无膜的血液界面，用于在血液和室内空气之间交换氧气和二氧化碳。我们的最终目标是开发一种完全可植入的人工肺用于慢性护理，尽管我们的技术可以用于其他并行设备，沿着这一最终目标。